Journal
KIDNEY INTERNATIONAL
Volume 76, Issue 4, Pages 376-382Publisher
ELSEVIER SCIENCE INC
DOI: 10.1038/ki.2009.231
Keywords
anemia; mTOR; posttransplant; renal; sirolimus
Categories
Funding
- MediMedia Educational Group
Ask authors/readers for more resources
Posttransplant anemia is a common problem that may hinder patients' quality of life. It occurs in 12 to 76% of patients, and is most common in the immediate posttransplant period. A variety of factors have been identified that increase the risk of posttransplant anemia, of which the level of renal function is most important. Sirolimus, a mammalian target of rapamycin inhibitor, has been implicated as playing a special role in posttransplant anemia. This review considers anemia associated with sirolimus, including its presentation, mechanisms, and management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available